Berlin – A novel collaborative funding initiative between the Milken Institute and the Ann Theodore Foundation (ATF) aims to accelerate research into sarcoidosis, a complex inflammatory disease that can affect multiple organs. The program, known as the ATF Sarcoidosis Inhibitor of mTOR (SIM) Trial, will provide up to $575,000 over two years to support a Phase 2 clinical trial investigating the potential of mTOR inhibitors in treating cutaneous sarcoidosis, a manifestation of the disease affecting the skin. This funding represents a significant step towards addressing a historically underfunded area of medical research and offers hope for improved treatment options for those living with this debilitating condition.
Sarcoidosis is characterized by the formation of granulomas – abnormal collections of immune cells – in various organs, most commonly the lungs and skin. While some cases resolve on their own, others turn into chronic and can lead to significant health problems. Cutaneous sarcoidosis, affecting approximately 25% of individuals with the disease, can manifest as painful skin rashes, lesions, and subcutaneous nodules. Currently, treatment options primarily focus on managing symptoms with general anti-inflammatory medications, which do not address the underlying causes of the disease. The lack of targeted therapies underscores the urgent need for innovative research, and the ATF-SIM trial represents a focused effort to fill this critical gap.
The decision to focus on mTOR inhibitors stems from promising preliminary findings. A small clinical trial conducted in 2024 suggested that sirolimus, an mTOR inhibitor already approved for other inflammatory conditions, demonstrated a significant positive impact on symptoms in seven out of ten participants with cutaneous sarcoidosis. News-Medical.net reported on this development, highlighting the potential of this therapeutic approach. This initial success has spurred the ATF and Milken Institute to invest in a larger, more comprehensive trial to validate these findings and pave the way for potential regulatory approval.
Addressing a Critical Funding Gap in Sarcoidosis Research
The ATF-SIM trial is the third collaborative funding program launched by the Milken Institute and the ATF to support biomedical research into sarcoidosis. Prior initiatives include ATF-LOMAS (Learning Opportunities in Medicine and Sarcoidosis) and ATF-BSI (Breakthrough Sarcoidosis Initiative), with the latter having already committed over $11 million to sarcoidosis research since 2020. The Milken Institute emphasizes that a key objective of this partnership is to reverse the historical pattern of limited funding for sarcoidosis research. This commitment is further demonstrated by the publication of a “Giving Smarter Guide,” which identifies strategic opportunities for philanthropic investment in the field.
Melissa Stevens, Executive Vice President of Strategic Philanthropy at the Milken Institute, underscored the importance of continued research. “People living with sarcoidosis, which can be extremely painful and unpredictable, do not currently have the treatment options they deserve,” Stevens stated. “To advance this potential treatment towards late-stage clinical trials and regulatory approval for use in treating cutaneous sarcoidosis, researchers must continue to demonstrate that an mTOR inhibitor has a significant effect in a new trial with more participants. We are excited to operate with ATF to ensure the sector accomplishes this next step as quickly as possible.”
Understanding the mTOR Pathway and its Role in Sarcoidosis
The mechanistic target of rapamycin (mTOR) pathway is a crucial regulator of cell growth, proliferation, and survival. Dysregulation of this pathway has been implicated in a variety of diseases, including cancer and autoimmune disorders. Recent research suggests that the mTOR pathway is likewise abnormally activated in sarcoidosis, contributing to the excessive immune response and granuloma formation characteristic of the disease. By inhibiting mTOR, researchers hope to dampen this immune response and reduce inflammation, ultimately alleviating the symptoms of sarcoidosis.
Sirolimus, the mTOR inhibitor used in the initial trial, is already approved by the U.S. Food and Drug Administration (FDA) for preventing organ rejection in transplant patients and treating certain types of cancer. The FDA’s prior approval of sirolimus for other indications offers a potential advantage in terms of safety and regulatory pathways, potentially accelerating the development of this treatment for sarcoidosis. However, it’s crucial to note that the effects of sirolimus in sarcoidosis may differ from its effects in other conditions, necessitating rigorous clinical testing.
Eligibility and Application Details for the ATF-SIM Trial
The ATF-SIM program is open to applications from independent biomedical researchers at qualifying research institutions worldwide. The program will award up to six two-year research grants. Projects led by individual researchers are eligible for up to $230,000 per year (including indirect costs), totaling $460,000 over two years. Interdisciplinary teams, defined as collaborations between a sarcoidosis expert and a researcher from a related field, or a team combining basic science and clinical expertise, can receive up to $287,500 per year, totaling $575,000 over two years. The application deadline is Monday, January 19, 2026, with funding decisions expected in June 2026, according to information provided by the Milken Institute application portal.
Lisa Spalding, a spokesperson for the Ann Theodore Foundation, emphasized the organization’s commitment to supporting research at all stages of development. “At ATF, we believe we owe the sarcoidosis community to support promising research directions at all stages of development, including this timely opportunity to accelerate a potential short-term treatment,” Spalding stated. “ATF-SIM augments, but does not supplant, our parallel efforts to support early-stage biomedical research and the development of a long-term scientific community through two other grant programs, which will yield benefits for decades to come. We must pursue all possible avenues to improve daily symptom management towards long-term symptom relief.”
Looking Ahead: The Potential Impact of the ATF-SIM Trial
The ATF-SIM trial represents a crucial step forward in the fight against sarcoidosis, particularly for individuals suffering from the cutaneous form of the disease. If successful, this research could lead to the development of a much-needed targeted therapy, offering significant relief to patients and improving their quality of life. The trial’s focus on mTOR inhibitors also has the potential to shed light on the underlying mechanisms of sarcoidosis, paving the way for the development of even more effective treatments in the future.
The Ann Theodore Foundation’s Breakthrough Sarcoidosis Initiative (ATF-BSI) has already invested over $11 million in sarcoidosis research, demonstrating a long-term commitment to understanding and treating this complex disease. The Ann Theodore Foundation’s website provides further information on their research initiatives and ongoing efforts to support the sarcoidosis community.
Applications for the ATF-SIM program are currently being accepted until April 20, 2026, at 11:59 PM Eastern Time. Researchers interested in applying are encouraged to review the full Request for Proposals for detailed eligibility criteria and application guidelines. The results of this trial are eagerly anticipated by the sarcoidosis community and the broader medical research field, offering a beacon of hope for those affected by this challenging condition.
Key Takeaways:
- The ATF-SIM trial will fund a Phase 2 clinical trial investigating mTOR inhibitors for cutaneous sarcoidosis.
- The program represents a significant investment in a historically underfunded area of medical research.
- Preliminary data suggest that sirolimus, an mTOR inhibitor, may be effective in treating cutaneous sarcoidosis.
- The application deadline for the grant is April 20, 2026.
Stay informed about the progress of the ATF-SIM trial and other advancements in sarcoidosis research. Share this article with your network to raise awareness of this important initiative. Your support can help accelerate the search for effective treatments and improve the lives of those living with sarcoidosis.